3 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 1 | 1 | Terminated 1 |
Follow dinaciclib: new trials by email Literature Review of dinaciclib trials Research Report on dinaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dinaciclib in Treating Patients With Stage III-IV Melanoma dinaciclib, pharmacological study, laboratory biomarker analysis - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2009-09-01 | 2017-04-04 |
| SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) SCH 727965, Bortezomib, Alemtuzumab - Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 8 | 2009-03-01 | 2015-08-07 |
| SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) SCH 727965, Gemtuzumab ozogamicin - Leukemia, Myeloid, Acute, Lymphoblastic Leukemia, Acute | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 29 | 2009-01-01 | 2015-02-04 |
Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Mantle-Cell (1) · Melanoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Merck Sharp & Dohme LLC (2) · National Cancer Institute (NCI) (1)
United States (1)
Frank Hodi (1)
P30CA006516 (1), U01CA062490 (1)